...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.
【24h】

Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease.

机译：血浆降甘油三酸酯和心血管事件治疗新靶点和通过积极降脂试验降低他汀类药物在冠心病患者中的新靶点并逐步降低终点。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We determined the ability of in-trial measurements of triglycerides (TGs) to predict new cardiovascular events (CVEs) using data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials. The trials compared atorvastatin 80 mg/day with moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT) in patients with clinically evident coronary heart disease or a history of myocardial infarction. The outcome measurement in the present research was CVE occurring after the first year of the trial. After adjusting for age, gender, and study, risk of CVEs increased with increasing TGs (p <0.001 for trend across quintiles of TGs). Patients in the highest quintile had a 63% higher rate of CVEs than patients in the lowest quintile (hazard ratio 1.63, 95% confidence interval 1.46 to 1.81) and the relation of TGs to risk was apparent even within the normal range of TGs. The ability of TG measurements to predict risk decreased when high-density lipoprotein cholesterol and apolipoprotein B:apolipoprotein A-1 were included in the statistical analysis, and it was abolished with inclusion of further variables (diabetes, body mass index, glucose, hypertension, and smoking; (p = 0.044 and 0.621, respectively, for trend across quintiles of TGs). Similar results were obtained in patients in whom low-density lipoprotein cholesterol had been lowered to guideline-recommended levels. In conclusion, even slightly increased TG levels are associated with higher risk of recurrence of CVEs in statin-treated patients and should be considered a useful marker of risk.
机译：我们使用激进降脂（IDEAL）和治疗新靶点（TNT）试验得出的终点递增数据，确定了甘油三酸酯（TGs）的临床测量预测新心血管事件（CVE）的能力。该试验比较了具有临床明显冠心病或有心肌梗塞病史的患者，将阿托伐他汀80 mg /天与中剂量他汀类药物疗法（IDEAL为辛伐他汀20-40 mg /天，TNT为阿托伐他汀10 mg /天）。在本研究中，结局指标是试验第一年后发生的CVE。在调整了年龄，性别和研究后，CVEs的风险随着TGs的增加而增加（TGs的五分之一趋势p <0.001）。五分位数最高的患者的CVE发生率比五分位数最低的患者高63％（危险比1.63，95％置信区间1.46至1.81），即使在正常TGs范围内，TGs与风险的关系也很明显。当统计分析中包括高密度脂蛋白胆固醇和载脂蛋白B：载脂蛋白A-1时，TG测量预测风险的能力降低，并且由于包括其他变量（糖尿病，体重指数，葡萄糖，高血压，吸烟和吸烟;（TG的五分位数趋势分别为p = 0.044和0.621）在低密度脂蛋白胆固醇降低至指南推荐水平的患者中也获得了类似的结果。他汀类药物治疗的患者中CVEs复发的风险较高，因此应被视为有用的风险标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号